Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of GLPG4059 in healthy male volunteers
NL-OMON55090Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG4059 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Galapagos NV. Primary endpoint: Safety and tolerability. Started Sep 2020; status: completed.
02
Drugs
GLPG4059
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON55090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55090.